Biliary tract cancer

Related records

Broader conditions (21)

• Biliary tract disorder
• Biliary tract neoplasm
• Cancer
• Cancer or benign tumor
• Digestive system cancer
• Digestive system disorder
• Digestive system neoplasm
• Disease
• Disease by body system or component
• Disease by etiologic mechanism
• Endocrine gland neoplasm
• Endocrine system disorder
• Hepatobiliary disorder
• Hepatobiliary neoplasm
• Human disease
• Liver and intrahepatic bile duct neoplasm
• Liver cancer
• Liver disorder
• Malignant endocrine neoplasm
• Neoplasm

Narrower conditions (48)

• Adenocarcinoma of gallbladder and extrahepatic biliary tract
• Adenosquamous bile duct carcinoma
• Ampulla of vater adenocarcinoma
• Ampulla of vater adenosquamous carcinoma
• Ampulla of vater cancer
• Ampulla of vater clear cell adenocarcinoma
• Ampulla of vater mucinous adenocarcinoma
• Ampulla of vater small cell neuroendocrine carcinoma
• Ampulla of vater squamous cell carcinoma
• Ampullary signet ring cell adenocarcinoma
• Bile duct adenocarcinoma
• Bile duct cancer
• Bile duct carcinoma
• Bile duct carcinoma in situ
• Bile duct sarcoma
• Biliary cystadenocarcinoma
• Carcinoma in situ of extrahepatic bile duct
• Carcinoma of the ampulla of vater
• Cholangiocarcinoma
• Cholangiolocellular carcinoma

Trials (326)

• A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
• A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract Cancer
• A COMPREHENSIVE BIOMARKER EVALUATION IN BILIARY TRACT CANCER
• A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer
• A Phase 1 Study of LNCB74 in Advanced Solid Tumors
• A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
• A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
• A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
• A Phase 1/2 Study of SC-43 in Combination With Cisplatin
• A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC)
• A Phase I Study of Adjuvant Chemotherapy With GC in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy
• A Phase I Study of Adjuvant Chemotherapy With GS in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy
• A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
• A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC
• A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer
• A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy.
• A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer
• A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Biliary Tract Cancers
• A Phase II Trial of Preoperative Chemotherapy for Biliary Tract Cancer (BTC) With Node Metastasis
• A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)

Approved drugs (1)

• Zanidatamab

Drugs in development (77)

• Abemaciclib Phase 2
• Adebrelimab Phase 2
• Asciminib Phase 1
• Atezolizumab Phase 2
• Becatecarin Phase 3
• Becotatug vedotin Phase 2
• Benmelstobart Phase 2
• Bevacizumab Phase 2
• Binimetinib Phase 3
• Cadonilimab Phase 2
• Camrelizumab Phase 2
• Capecitabine Phase 3
• Carboplatin Phase 3
• Catequentinib Phase 2
• Cisplatin Phase 3
• CPI 613 Phase 1
• Cyclophosphamide Phase 1
• Dextrose Phase 2
• DKN-01 Phase 2
• Docetaxel Phase 2

Other linked drugs (3)

• E-7090
• Futibatinib
• Pemigatinib